A Pan-Respiratory Antiviral Chemotype Targeting a Host Multi-Protein Complex

作者：Maya Michon, Andreas Müller‐Schiffmann, Anuradha F. Lingappa, Shao Feng Yu, Li Du, Fred Deiter, Sean Broce, Suguna Mallesh, Jackelyn Crabtree, Usha Lingappa, Amanda Macieik, Lisa Müller, Philipp Niklas Ostermann, Marcel Andrée, Ortwin Adams, Heiner Schaal, Robert J. Hogan, Ralph A. Tripp, Umesh Appaiah, Sanjeev K. Anand, Thomas W. Campi, Michael Ford, Jonathan C. Reed, Jim Jung‐Ching Lin, Olayemi Akintunde, Kiel Copeland, Christine Nichols, Emma Petrouski, Alvaro Moreira, I-ting Jiang, Nicholas DeYarman, Ian H. Brown, Sharon Lau, Ilana Segal, Danielle Goldsmith, Shi Hong, Vinod Asundi, Erica M. Briggs, Ngwe Sin Phyo, Markus Froehlich, Bruce Onisko, Kent Matlack, Debendranath Dey, Jaisri R. Lingappa, M. Dharma Prasad, Anatoliy Kitaygorodskyy, Dennis Solas, Homer A. Boushey, John R. Greenland, Satish K. Pillai, Michael K. Lo, Joel M. Montgomery, Christina F. Spiropoulou, Carsten Korth, Suganya Selvarajah, Kumar Paulvannan, Vishwanath R. Lingappa · 发表于：bioRxiv (Cold Spring Harbor Laboratory) · 年份：2021 · DOI：10.1101/2021.01.17.426875 · 被引用次数：10 · 研究领域：Viral Infectious Diseases and Gene Expression in Insects、14-3-3 protein interactions、Monoclonal and Polyclonal Antibodies Research

We present a novel small molecule antiviral chemotype that was identified by an unconventional cell-free protein synthesis and assembly-based phenotypic screen for modulation of viral capsid assembly. Activity of PAV-431, a representative compound from the series, has been validated against infectious virus in multiple cell culture models for all six families of viruses causing most respiratory disease in humans. In animals this chemotype has been demonstrated efficacious for Porcine Epidemic Diarrhea Virus (a coronavirus) and Respiratory Syncytial Virus (a paramyxovirus). PAV-431 is shown to bind to the protein 14-3-3, a known allosteric modulator. However, it only appears to target the small subset of 14-3-3 which is present in a dynamic multi-protein complex whose components include proteins implicated in viral lifecycles and in innate immunity. The composition of this target multi-protein complex appears to be modified upon viral infection and largely restored by PAV-431 treatment. Our findings suggest a new paradigm for understanding, and drugging, the host-virus interface, which leads to a new clinical therapeutic strategy for treatment of respiratory viral disease.